bluuebunny/crossref_metadata_2025 huggingface dataset:
Data from A Randomized Double-blind Placebo-controlled Trial of Oral Aspirin for Protection of Melanocytic Nevi Against UV-induced DNA Damage
Authors: Okwundu Nwanneka , Rahman Hafeez , Liu Tong , Florell Scott R. , Boucher Kenneth M. , Grossman Douglas
Published: April 2023

Abstract
DNA damage plays a role in ultraviolet (UV)-induced melanoma. We previously showed that aspirin (ASA) can suppress prostaglandin-E2 (PGE2) and protect melanocytes from UV-induced DNA damage in mice, and suggested that taking ASA before acute sun exposure may reduce melanoma risk. We conducted a prospective randomized placebo-controlled trial to determine if orally administered ASA could suppress PGE2 in plasma and nevi and protect nevi from UV-induced DNA damage. After obtaining plasma and determining the minimal erythemal dose (MED) in 95 subjects at increased risk for melanoma, they were randomized to receive a daily dose of placebo, 81 mg ASA, or 325 mg ASA, in double-blind fashion for one month. After this intervention, one nevus was irradiated (dose = 1 or 2 MED) using a solar simulator. One day later, MED was re-determined, a second plasma sample was obtained, and the UV-irradiated nevus and an unirradiated nevus were removed. ASA metabolites were detected in the second plasma sample in subjects in the ASA arms. There were no significant differences in the pre- and post-intervention MED between those patients receiving ASA and placebo. Significantly reduced PGE2 levels were detected in plasma (second vs. first samples) and in nevi (both unirradiated and UV-treated) in subjects receiving ASA compared to placebo. Comparing UV-treated nevi from the ASA and placebo cohorts, however, did not reveal significant reductions in CD3-cell infiltration or 8-oxoguanine and cyclobutane pyrimidine dimers. Thus ASA did not effectively protect nevi from solar-simulated UV-induced inflammation and DNA damage under the conditions examined.
Prevention Relevance:
Despite promising rationale, ASA at conventional dosing was not able to protect nevi against UV-induced DNA damage under the conditions examined.

See related Spotlight, p. 71.
Data from The Ashitaba (Angelica keiskei) Chalcones 4-hydroxyderricin and Xanthoangelol Suppress Melanomagenesis By Targeting BRAF and PI3K
Authors: Zhang Tianshun , Wang Qiushi , Fredimoses Mangaladoss , Gao Ge , Wang Keke , Chen Hanyong , Wang Ting , Oi Naomi , Zykova Tatyana A. , Reddy Kanamata , Yao Ke , Ma Weiya , Chang Xiaoyu , Lee Mee-Hyun , Rathore Moeez Ghani , Bode Ann M. , Ashida Hitoshi , Lippman Scott M. , Dong Zigang
Published: April 2023

Abstract
Malignant melanoma is an aggressive tumor of the skin and still lacks effective preventive and therapeutic treatments. In melanoma, both the BRAF/MEK/ERK and PI3-K/AKT signaling pathways are constitutively activated through multiple mechanisms, which result in cell-cycle progression and prevention of apoptosis. Therefore, the development of novel strategies for targeting BRAF and PI3K are of utmost importance. In this study, we found that Ashitaba (Angelica keiskei) chalcones, 4-hydroxyderricin (4HD) and xanthoangelol (XAG), suppressed melanoma development by directly targeting both BRAFV600E and PI3K, which blocked the activation of downstream signaling. This led to the induction of G1 phase cell-cycle arrest and apoptosis in melanoma cells. Importantly, 4HD or XAG dramatically attenuated tumor incidence and volume in the BRAF-activated Pten-deficient melanoma mouse model. Our findings suggest that 4HD and XAG are promising chemopreventive or potential therapeutic agents against melanomagenesis that act by targeting both BRAF and PI3K, providing hope for rapid clinical translation. Cancer Prev Res; 11(10); 607–20. ©2018 AACR.
Data from Age at Initiation and Frequency of Screening to Prevent Esophageal Squamous Cell Carcinoma in High-risk Regions: an Economic Evaluation
Authors: Wu Bin , Wang Zhenhua , Zhang Qiang
Published: April 2023

Abstract
The aim of this study was to identify the economic screening strategies for esophageal squamous cell carcinoma (ESCC) in high-risk regions. We used a validated ESCC health policy model for comparing different screening strategies for ESCC. Strategies varied in terms of age at initiation and frequency of screening. Model inputs were derived from parameter calibration and published literature. We estimated the effects of each strategy on the incidence of ESCC, costs, quality-adjusted life-year (QALY), and incremental cost-effectiveness ratios (ICERs). Compared with no screening, all competing screening strategies decreased the incidence of ESCC from 0.35% to 72.8%, and augmented the number of QALYs (0.002-0.086 QALYs per person) over a lifetime horizon. The screening strategies initiating at 40 years of age and repeated every 1–3 years, which gained over 70% of probabilities that was preferred in probabilistic sensitivity analysis at a $1,151/QALY willingness-to-pay threshold. Results were sensitive to the parameters related to the risks of developing basal cell hyperplasia/mild dysplasia. Endoscopy screening initiating at 40 years of age and repeated every 1–3 years could substantially reduce the disease burden and is cost-effective for the general population in high-risk regions.
Data from Reducing Fatty Acid Oxidation Improves Cancer-free Survival in a Mouse Model of Li-Fraumeni Syndrome
Authors: Wang Ping-Yuan , Ma Jin , Li Jie , Starost Matthew F. , Wolfgang Michael J. , Singh Komudi , Pirooznia Mehdi , Kang Ju-Gyeong , Hwang Paul M.
Published: April 2023

Abstract
Germline mutations of TP53, which cause the cancer predisposition disorder Li-Fraumeni syndrome (LFS), can increase mitochondrial activity as well as fatty acid β-oxidation (FAO) in mice. Increased fatty acid metabolism can promote cancer malignancy, but its specific contribution to tumorigenesis in LFS remains unclear. To investigate this, we crossed LFS mice carrying the p53 R172H knock-in mutation (p53172H/H, homolog of the human TP53 R175H LFS mutation) with myoglobin-knockout (MB−/−) mice known to have decreased FAO. MB−/− p53172H/H double-mutant mice also showed mildly reduced FAO in thymus, a common site of T lymphoma development in LFS mice, in association with an approximately 40% improvement in cancer-free survival time. RNA sequencing profiling revealed that the p53 R172H mutation promotes mitochondrial metabolism and ribosome biogenesis, both of which are suppressed by the disruption of MB. The activation of ribosomal protein S6, involved in protein translation and implicated in cancer promotion, was also inhibited in the absence of MB. To further confirm the role of FAO in lymphomagenesis, mitochondrial FAO enzyme, carnitine palmitoyltransferase 2 (CPT2), was specifically disrupted in T cells of p53172H/H mice using a Cre-loxP–mediated strategy. The heterozygous knockout of CPT2 resulted in thymus FAO haploinsufficiency and an approximately 30% improvement in survival time, paralleling the antiproliferative signaling observed with MB disruption. Thus, this study demonstrates that moderating FAO in LFS can suppress tumorigenesis and improve cancer-free survival with potential implications for cancer prevention.
Prevention Relevance:
Mildly inhibiting the increased fatty acid oxidation observed in a mouse model of Li-Fraumeni syndrome, a cancer predisposition disorder caused by inherited mutations of TP53, dampens aberrant pro-tumorigenic cell signaling and improves the survival time of these mice, thereby revealing a potential strategy for cancer prevention in patients.
Data from Plasma 25-Hydroxyvitamin D, Vitamin D Binding Protein, and Risk of Colorectal Cancer in the Nurses' Health Study
Authors: Song Mingyang , Konijeti Gauree Gupta , Yuan Chen , Ananthakrishnan Ashwin N. , Ogino Shuji , Fuchs Charles S. , Giovannucci Edward L. , Ng Kimmie , Chan Andrew T.
Published: April 2023

Abstract
Total circulating 25-hydroxyvitamin D [25(OH)D)] has been associated with lower risk of colorectal cancer. The physiologic mechanism, however, may be more directly related to the free or bioavailable fraction of 25(OH)D, which is influenced by levels of vitamin D binding protein (VDBP). We assessed the association of prediagnosis total, free, and bioavailable 25(OH)D and VDBP with colorectal cancer risk among predominantly white women in the Nurses' Health Study (NHS) who provided a blood specimen in 1989–1990. We documented 378 cases of colorectal cancer through 2011 and matched them to 689 controls according to age and time of blood draw. We genotyped two common polymorphisms in the gene coding VDBP and calculated free and bioavailable 25(OH)D levels based on total 25(OH)D, VDBP, albumin, and their estimated genotype-specific binding affinities. Total 25(OH)D was associated with lower colorectal cancer risk (P for trend = 0.01). Compared with women in the lowest quintile of total 25(OH)D, those in the highest quintile had a multivariable-adjusted odds ratio (OR) for colorectal cancer of 0.54 [95% confidence interval (CI), 0.33–0.87]. Comparing extreme quintiles, we did not find any significant association with risk of colorectal cancer for VDBP (OR, 0.98; 95% CI, 0.65–1.47), free 25(OH)D (OR, 0.71; 95% CI, 0.46–1.10), or bioavailable 25(OH)D (OR, 0.92; 95% CI, 0.60–1.42). In conclusion, prediagnosis levels of total, but not free or bioavailable 25(OH)D, were associated with lower colorectal cancer risk. Although our findings support an inverse association of vitamin D with colorectal cancer, this association does not appear to be due to the unbound or bioavailable fraction of circulating vitamin D. Cancer Prev Res; 9(8); 664–72. ©2016 AACR.
Data from Mushroom Consumption and Risk of Total and Site-Specific Cancer in Two Large U.S. Prospective Cohorts
Authors: Lee Dong Hoon , Yang Meng , Keum NaNa , Giovannucci Edward L. , Sun Qi , Chavarro Jorge E.
Published: April 2023

Abstract
Several case–control studies have reported that mushroom consumption may be associated with reduced risk of certain cancers. However, epidemiologic studies have not yet prospectively examined the association of mushroom consumption with total and various site-specific cancer risks. This prospective cohort study included 68,327 women (Nurses' Health Study, 1986–2012) and 44,664 men (Health Professionals Follow-up Study, 1986–2012) who were free of cancer at baseline. Mushroom consumption was assessed at baseline using a validated food frequency questionnaire. Covariates were assessed using biennial questionnaires during the follow-up. We used Cox proportional hazards models to estimate hazard ratios (HR) and 95% confidence intervals (CI) of total and 17 site-specific cancers associated with mushroom consumption. During up to 26 years of follow-up, we documented 22,469 incident cancer cases (15,103 in women and 7,366 in men). In the pooled multivariable analysis, participants who consumed five or more servings of mushrooms per week had no significantly different risk of total cancer (HR, 1.06; 95% CI, 0.98–1.14) than participants who almost never consumed mushrooms. We consistently found no association between mushroom consumption and risk of 16 site-specific cancers. However, there was a marginal positive association between mushroom consumption and risk of lung cancer (Ptrend = 0.05). In conclusion, we found no association between mushroom consumption and total and site-specific cancers in U.S. women and men. More prospective cohort studies are needed to examine the associations for specific cancer types in diverse racial/ethnic groups.
Data from Physical Activity and Risk of Hepatocellular Carcinoma Among U.S. Men and Women
Authors: Luo Xiao , Yang Wanshui , Ma Yanan , Simon Tracey G. , Meyerhardt Jeffrey A. , Chan Andrew T. , Giovannucci Edward L. , Zhang Xuehong
Published: April 2023

Abstract
Mounting evidence indicates a potential beneficial effect of vigorous-intensity physical activity on hepatocellular carcinoma (HCC). However, the association between moderate-intensity physical activity, such as brisk walking, and the risk of HCC remains largely unknown. Two prospective cohorts of 77,535 women from the Nurses' Health Study and 44,540 men from the Health Professionals Follow-up Study were included. Weekly time spent on physical activities were updated biennially. The Cox proportional hazard regression model was used to calculate multivariable hazard ratios (HR) and 95% confidence intervals (95% CI). After an average 23-year follow-up, we identified 138 incident HCC cases. A higher amount of total physical activity was not significantly associated with a reduced risk of HCC (top tertile vs. bottom tertile; HR = 0.78; 95% CI, 0.51–1.18; Ptrend = 0.33). For the same comparison, there was an inverse association between moderate-intensity activity and HCC risk (HR = 0.60; 95% CI, 0.38–0.94; Ptrend = 0.04), whereas no statistically significant association with vigorous-intensity activity (HR = 0.88; 95% CI, 0.56–1.37; Ptrend = 0.74). Engaging in brisk walking was significantly associated with a lower risk of HCC (over 1 hour/week vs. non-brisk walking; HR = 0.50; 95% CI, 0.31–0.78; Ptrend = 0.006). The association between brisk walking and HCC risk was generally present across all subgroups, including age, body mass index, type 2 diabetes mellitus, smoking status, aspirin use, and alcohol consumption (all Pinteraction ≥ 0.05). In conclusion, moderate-intensity activity, especially brisk walking, was associated with reduced risk of HCC among U.S. men and women. If confirmed, brisk walking might serve a feasible way for HCC prevention.
Data from Temporal Efficacy of a Sulforaphane-Based Broccoli Sprout Diet in Prevention of Breast Cancer through Modulation of Epigenetic Mechanisms
Authors: Li Yuanyuan , Buckhaults Phillip , Li Shizhao , Tollefsbol Trygve
Published: April 2023

Abstract
Breast cancer is the most common cancer and the second leading cause of cancer-related death among women. An important risk factor for breast cancer is individual genetic background, which is initially generated early in human life, for example, during the processes of embryogenesis and fetal development in utero. Bioactive dietary components such as sulforaphane (SFN), an isothiocyanate from cruciferous vegetables including broccoli sprouts (BSp), cabbage, and kale, has been shown to reduce the risk of developing many common cancers through regulation of epigenetic mechanisms. Our study indicates a prenatal/maternal BSp dietary treatment exhibited maximal preventive effects in inhibiting breast cancer development compared with postnatal early-life and adult BSp treatments in two transgenic mouse models that can develop breast cancer. Postnatal early-life BSp treatment starting prior to puberty onset showed protective effects in prevention of breast cancer but was not as effective as the prenatal/maternal BSp treatment. However, adulthood-administered BSp diet did not reduce mammary tumorigenesis. Our results suggest that the prenatal/maternal BSp bioactive natural plant product may impact early embryonic development by regulating global differential gene expression through affecting epigenetic profiles resulting in differential susceptibility to breast cancer later in life. These results suggest that a temporal exposure to epigenetic-modulating dietary components such as cruciferous vegetables could be a key factor for maximizing chemopreventive effects on human breast cancer. This study may lead to translational breast cancer chemopreventive potential by appropriate administration of key dietary components leading to early breast cancer prevention in humans. Cancer Prev Res; 11(8); 451–64. ©2018 AACR.
Data from δ-Tocotrienol is the Most Potent Vitamin E Form in Inhibiting Prostate Cancer Cell Growth and Inhibits Prostate Carcinogenesis in Ptenp−/− Mice
Authors: Wang Hong , Yan William , Sun Yuhai , Yang Chung S.
Published: April 2023

Abstract
Vitamin E compounds, consisting of α, β, γ, and δ forms of tocopherols and tocotrienols, display different cancer preventive activities in experimental models. Tocotrienols may have higher potential for clinical use due to their lower effective doses in laboratory studies. However, most studies on tocotrienols have been carried out using cancer cell lines. Strong data from animal studies may encourage the use of tocotrienols for human cancer prevention research. To examine the cancer inhibitory activity of different vitamin E forms, we first investigated their inhibitory activities of different vitamin E forms in prostate cancer cell lines. We found that δ-tocotrienol (δT3) was the most effective form in inhibiting cell growth at equivalent doses. Because of this in vitro potency, δT3 was further studied using prostate-specific Pten−/− (Ptenp−/−) mice. We found that 0.05% δT3 in diet reduced prostate adenocarcinoma multiplicity by 32.7%, featuring increased apoptosis and reduced cell proliferation. The inhibitory effect of 0.05% δT3 in diet was similar to that of 0.2% δ-tocopherol (δT) in diet reported previously. Our further study on the δT3-induced transcriptome changes indicated that δT3 inhibited genes in blood vessel development in the prostate of Ptenp−/− mice, which was confirmed by IHC. Together, our results demonstrate that δT3 effectively inhibits the development of prostate adenocarcinoma in Ptenp−/− mice, which involves inhibition of proliferation and angiogenesis and promotion of apoptosis.
Prevention Relevance:
We demonstrated that δ-tocotrienol is the most active vitamin E form in inhibiting the growth of several prostate cancer cell lines. In transgenic Ptenp−/− mice, δ-tocotrienol inhibited the formation of prostate cancer. This result would encourage and help design clinical studies for the application of δ-tocotrienol for prostate cancer prevention.
Data from A Randomized Phase IIb Trial of myo-Inositol in Smokers with Bronchial Dysplasia
Authors: Lam Stephen , Mandrekar Sumithra J. , Gesthalter Yaron , Allen Ziegler Katie L. , Seisler Drew K. , Midthun David E. , Mao Jenny T. , Aubry Marie Christine , McWilliams Annette , Sin Don D. , Shaipanich Tawimas , Liu Gang , Johnson Evan , Bild Andrea , Lenburg Marc E. , Ionescu Diana N. , Mayo John , Yi Joanne (Eunhee) , Tazelaar Henry , Harmsen William S. , Smith Judith , Spira Avrum E. , Beane Jennifer , Limburg Paul J. , Szabo Eva
Published: April 2023

Abstract
Previous preclinical studies and a phase I clinical trial suggested that myo-inositol may be a safe and effective lung cancer chemopreventive agent. We conducted a randomized, double blind, placebo-controlled phase IIb study to determine the chemopreventive effects of myo-inositol in smokers with bronchial dysplasia. Smokers with ≥1 site of dysplasia identified by autofluorescence bronchoscopy-directed biopsy were randomly assigned to receive oral placebo or myo-inositol, 9 g once a day for 2 weeks, and then twice a day for 6 months. The primary endpoint was change in dysplasia rate after 6 months of intervention on a per-participant basis. Other trial endpoints reported herein include Ki-67 labeling index, blood and bronchoalveolar lavage fluid (BAL) levels of proinflammatory, oxidant/antioxidant biomarkers, and an airway epithelial gene expression signature for PI3K activity. Seventy-four (n = 38 myo-inositol and n = 36 placebo) participants with a baseline and 6-month bronchoscopy were included in all efficacy analyses. The complete response and the progressive disease rates were 26.3% versus 13.9% and 47.4% versus 33.3%, respectively, in the myo-inositol and placebo arms (P = 0.76). Compared with placebo, myo-inositol intervention significantly reduced IL6 levels in BAL over 6 months (P = 0.03). Among those with a complete response in the myo-inositol arm, there was a significant decrease in a gene expression signature reflective of PI3K activation within the cytologically normal bronchial airway epithelium (P = 0.002). The heterogeneous response to myo-inositol suggests a targeted therapy approach based on molecular alterations is needed in future clinical trials to determine the efficacy of myo-inositol as a chemopreventive agent. Cancer Prev Res; 9(12); 906–14. ©2016 AACR.
Data from A Phase II Randomized Placebo-Controlled Trial of Oral N-acetylcysteine for Protection of Melanocytic Nevi against UV-Induced Oxidative Stress In Vivo
Authors: Cassidy Pamela B. , Liu Tong , Florell Scott R. , Honeggar Matthew , Leachman Sancy A. , Boucher Kenneth M. , Grossman Douglas
Published: April 2023

Abstract
Oxidative stress plays a role in UV-induced melanoma, which may arise from melanocytic nevi. We investigated whether oral administration of the antioxidant N-acetylcysteine (NAC) could protect nevi from oxidative stress in vivo in the setting of acute UV exposure. The minimal erythemal dose (MED) was determined for 100 patients at increased risk for melanoma. Patients were randomized to receive a single dose (1,200 mg) of NAC or placebo, in double-blind fashion, and then one nevus was irradiated (1–2 MED) using a solar simulator. One day later, the MED was redetermined and the irradiated nevus and a control unirradiated nevus were removed for histologic analysis and examination of biomarkers of NAC metabolism and UV-induced oxidative stress. Increased expression of 8-oxoguanine, thioredoxin reductase-1, and γ-glutamylcysteine synthase modifier subunit were consistently seen in UV-treated compared with unirradiated nevi. However, no significant differences were observed in these UV-induced changes or in the pre- and postintervention MED between those patients receiving NAC versus placebo. Similarly, no significant differences were observed in UV-induced changes between subjects with germline wild-type versus loss-of-function mutations in the melanocortin-1 receptor. Nevi showed similar changes of UV-induced oxidative stress in an open-label post-trial study in 10 patients who received NAC 3 hours before nevus irradiation. Thus, a single oral dose of NAC did not effectively protect nevi from UV-induced oxidative stress under the conditions examined. Cancer Prev Res; 10(1); 36–44. ©2016 AACR.
Data from Evidence that EZH2 Deregulation is an Actionable Therapeutic Target for Prevention of Prostate Cancer
Authors: Burkhart Deborah L. , Morel Katherine L. , Wadosky Kristine M. , Labbé David P. , Galbo Phillip M. , Dalimov Zafardjan , Xu Bo , Loda Massimo , Ellis Leigh
Published: April 2023

Abstract
Chemoprevention trials for prostate cancer by androgen receptor or androgen synthesis inhibition have proven ineffective. Recently, it has been demonstrated that the histone methlytransferase, EZH2 is deregulated in mouse and human high-grade prostatic intraepithelial neoplasia (HG-PIN). Using preclinical mouse and human models of prostate cancer, we demonstrate that genetic and chemical disruption of EZH2 expression and catalytic activity reversed the HG-PIN phenotype. Furthermore, inhibition of EZH2 function was associated with loss of cellular proliferation and induction of Tp53-dependent senescence. Together, these data provide provocative evidence for EZH2 as an actionable therapeutic target toward prevention of prostate cancer.
Supplementary Table 2 from Integrative Epigenomic Analysis Identifies Biomarkers and Therapeutic Targets in Adult B-Acute Lymphoblastic Leukemia
Authors: Geng Huimin , Brennan Sarah , Milne Thomas A. , Chen Wei-Yi , Li Yushan , Hurtz Christian , Kweon Soo-Mi , Zickl Lynette , Shojaee Seyedmehdi , Neuberg Donna , Huang Chuanxin , Biswas Debabrata , Xin Yuan , Racevskis Janis , Ketterling Rhett P. , Luger Selina M. , Lazarus Hillard , Tallman Martin S. , Rowe Jacob M. , Litzow Mark R. , Guzman Monica L. , Allis C. David , Roeder Robert G. , Müschen Markus , Paietta Elisabeth , Elemento Olivier , Melnick Ari M.
Published: April 2023

XLS file - 60K, Characteristics of the 215 E2993 B-ALL patients and the 12 normal bone marrow samples (excel file)
Supplementary Table 15 from Integrative Epigenomic Analysis Identifies Biomarkers and Therapeutic Targets in Adult B-Acute Lymphoblastic Leukemia
Authors: Geng Huimin , Brennan Sarah , Milne Thomas A. , Chen Wei-Yi , Li Yushan , Hurtz Christian , Kweon Soo-Mi , Zickl Lynette , Shojaee Seyedmehdi , Neuberg Donna , Huang Chuanxin , Biswas Debabrata , Xin Yuan , Racevskis Janis , Ketterling Rhett P. , Luger Selina M. , Lazarus Hillard , Tallman Martin S. , Rowe Jacob M. , Litzow Mark R. , Guzman Monica L. , Allis C. David , Roeder Robert G. , Müschen Markus , Paietta Elisabeth , Elemento Olivier , Melnick Ari M.
Published: April 2023

XLS file - 204K, Genomic regions enriched in MLLN, AF4C, H3K79me2 and the common of the three ChIP-seq in RS4;11 cells
Supplementary Tables 1-16, Figures 1-15 from Imaging Androgen Receptor Signaling with a Radiotracer Targeting Free Prostate-Specific Antigen
Authors: Ulmert David , Evans Michael J. , Holland Jason P. , Rice Samuel L. , Wongvipat John , Pettersson Kim , Abrahamsson Per-Anders , Scardino Peter T. , Larson Steven M. , Lilja Hans , Lewis Jason S. , Sawyers Charles L.
Published: April 2023

PDF file - 1.7MB
Supplementary Movie 9 from Ovarian Cancer Spheroids Use Myosin-Generated Force to Clear the Mesothelium
Authors: Iwanicki Marcin P. , Davidowitz Rachel A. , Ng Mei Rosa , Besser Achim , Muranen Taru , Merritt Melissa , Danuser Gaudenz , Ince Tan , Brugge Joan S.
Published: April 2023

File Type: .mov; File Size: 1.5 MB.
Supplementary Methods from A High-Throughput Functional Complementation Assay for Classification of BRCA1 Missense Variants
Authors: Bouwman Peter , van der Gulden Hanneke , van der Heijden Ingrid , Drost Rinske , Klijn Christiaan N. , Prasetyanti Pramudita , Pieterse Mark , Wientjens Ellen , Seibler Jost , Hogervorst Frans B.L. , Jonkers Jos
Published: April 2023

Supplementary Methods - PDF 55K, A detailed protocol for the classification of BRCA1 sequence variants using R26CreERT2/RMCE;Brca1SCo/{delta} ES cells
Supplementary Movie 3 from Ovarian Cancer Spheroids Use Myosin-Generated Force to Clear the Mesothelium
Authors: Iwanicki Marcin P. , Davidowitz Rachel A. , Ng Mei Rosa , Besser Achim , Muranen Taru , Merritt Melissa , Danuser Gaudenz , Ince Tan , Brugge Joan S.
Published: April 2023

File Type: .mov; File Size: <1 MB.
Supplementary Table 3 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
Authors: Littlepage Laurie E. , Adler Adam S. , Kouros-Mehr Hosein , Huang Guiqing , Chou Jonathan , Krig Sheryl R. , Griffith Obi L. , Korkola James E. , Qu Kun , Lawson Devon A. , Xue Qing , Sternlicht Mark D. , Dijkgraaf Gerrit J.P. , Yaswen Paul , Rugo Hope S. , Sweeney Colleen A. , Collins Colin C. , Gray Joe W. , Chang Howard Y. , Werb Zena
Published: April 2023

PDF file - 117K, Microarray target genes from MCF7 siRNA. Target genes identified by microarray expression analysis from MCF7 cells � Znf217 siRNA
Supplementary Movie from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
Authors: Littlepage Laurie E. , Adler Adam S. , Kouros-Mehr Hosein , Huang Guiqing , Chou Jonathan , Krig Sheryl R. , Griffith Obi L. , Korkola James E. , Qu Kun , Lawson Devon A. , Xue Qing , Sternlicht Mark D. , Dijkgraaf Gerrit J.P. , Yaswen Paul , Rugo Hope S. , Sweeney Colleen A. , Collins Colin C. , Gray Joe W. , Chang Howard Y. , Werb Zena
Published: April 2023

PDF file - 12MB, Movie of SCp2 cells infected with vector (left movie) or Znf217 (right movie) following a scratch with a pipette tip. This movie ran for 20.25 hours
Supplementary Methods, Figures 1-4, Movie Legend, Table Legends 1-5 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
Authors: Littlepage Laurie E. , Adler Adam S. , Kouros-Mehr Hosein , Huang Guiqing , Chou Jonathan , Krig Sheryl R. , Griffith Obi L. , Korkola James E. , Qu Kun , Lawson Devon A. , Xue Qing , Sternlicht Mark D. , Dijkgraaf Gerrit J.P. , Yaswen Paul , Rugo Hope S. , Sweeney Colleen A. , Collins Colin C. , Gray Joe W. , Chang Howard Y. , Werb Zena
Published: April 2023

PDF file - 2.4MB
Supplementary Table 8 from TYK2–STAT1–BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia
Authors: Sanda Takaomi , Tyner Jeffrey W. , Gutierrez Alejandro , Ngo Vu N. , Glover Jason , Chang Bill H. , Yost Arla , Ma Wenxue , Fleischman Angela G. , Zhou Wenjun , Yang Yandan , Kleppe Maria , Ahn Yebin , Tatarek Jessica , Kelliher Michelle A. , Neuberg Donna S. , Levine Ross L. , Moriggl Richard , Müller Mathias , Gray Nathanael S. , Jamieson Catriona H.M. , Weng Andrew P. , Staudt Louis M. , Druker Brian J. , Look A. Thomas
Published: April 2023

XLSX file - 24K, PCR Primer sequences.
Supplementary Figure 9 from TYK2–STAT1–BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia
Authors: Sanda Takaomi , Tyner Jeffrey W. , Gutierrez Alejandro , Ngo Vu N. , Glover Jason , Chang Bill H. , Yost Arla , Ma Wenxue , Fleischman Angela G. , Zhou Wenjun , Yang Yandan , Kleppe Maria , Ahn Yebin , Tatarek Jessica , Kelliher Michelle A. , Neuberg Donna S. , Levine Ross L. , Moriggl Richard , Müller Mathias , Gray Nathanael S. , Jamieson Catriona H.M. , Weng Andrew P. , Staudt Louis M. , Druker Brian J. , Look A. Thomas
Published: April 2023

PDF file - 113K, Bcl2 protein expression in wild-type and Tyk2 knockout mice.
Supplementary Figure 8 from TYK2–STAT1–BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia
Authors: Sanda Takaomi , Tyner Jeffrey W. , Gutierrez Alejandro , Ngo Vu N. , Glover Jason , Chang Bill H. , Yost Arla , Ma Wenxue , Fleischman Angela G. , Zhou Wenjun , Yang Yandan , Kleppe Maria , Ahn Yebin , Tatarek Jessica , Kelliher Michelle A. , Neuberg Donna S. , Levine Ross L. , Moriggl Richard , Müller Mathias , Gray Nathanael S. , Jamieson Catriona H.M. , Weng Andrew P. , Staudt Louis M. , Druker Brian J. , Look A. Thomas
Published: April 2023

PDF file - 105K, Signaling and cell cycle distribution after JAK inhibitor I treatment.
Supplementary Tables 1-8 from Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors
Authors: Vivanco Igor , Robins H. Ian , Rohle Daniel , Campos Carl , Grommes Christian , Nghiemphu Phioanh Leia , Kubek Sara , Oldrini Barbara , Chheda Milan G. , Yannuzzi Nicolas , Tao Hui , Zhu Shaojun , Iwanami Akio , Kuga Daisuke , Dang Julie , Pedraza Alicia , Brennan Cameron W. , Heguy Adriana , Liau Linda M. , Lieberman Frank , Yung W. K. Alfred , Gilbert Mark R. , Reardon David A. , Drappatz Jan , Wen Patrick Y. , Lamborn Kathleen R. , Chang Susan M. , Prados Michael D. , Fine Howard A. , Horvath Steve , Wu Nian , Lassman Andrew B. , DeAngelis Lisa M. , Yong William H. , Kuhn John G. , Mischel Paul S. , Mehta Minesh P. , Cloughesy Timothy F. , Mellinghoff Ingo K.
Published: April 2023

PDF file - 104K
Supplementary Figure and Table Legends, Methods from Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors
Authors: Vivanco Igor , Robins H. Ian , Rohle Daniel , Campos Carl , Grommes Christian , Nghiemphu Phioanh Leia , Kubek Sara , Oldrini Barbara , Chheda Milan G. , Yannuzzi Nicolas , Tao Hui , Zhu Shaojun , Iwanami Akio , Kuga Daisuke , Dang Julie , Pedraza Alicia , Brennan Cameron W. , Heguy Adriana , Liau Linda M. , Lieberman Frank , Yung W. K. Alfred , Gilbert Mark R. , Reardon David A. , Drappatz Jan , Wen Patrick Y. , Lamborn Kathleen R. , Chang Susan M. , Prados Michael D. , Fine Howard A. , Horvath Steve , Wu Nian , Lassman Andrew B. , DeAngelis Lisa M. , Yong William H. , Kuhn John G. , Mischel Paul S. , Mehta Minesh P. , Cloughesy Timothy F. , Mellinghoff Ingo K.
Published: April 2023

PDF file - 133K
Interview with Dr. Mellinghoff from Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors
Authors: Vivanco Igor , Robins H. Ian , Rohle Daniel , Campos Carl , Grommes Christian , Nghiemphu Phioanh Leia , Kubek Sara , Oldrini Barbara , Chheda Milan G. , Yannuzzi Nicolas , Tao Hui , Zhu Shaojun , Iwanami Akio , Kuga Daisuke , Dang Julie , Pedraza Alicia , Brennan Cameron W. , Heguy Adriana , Liau Linda M. , Lieberman Frank , Yung W. K. Alfred , Gilbert Mark R. , Reardon David A. , Drappatz Jan , Wen Patrick Y. , Lamborn Kathleen R. , Chang Susan M. , Prados Michael D. , Fine Howard A. , Horvath Steve , Wu Nian , Lassman Andrew B. , DeAngelis Lisa M. , Yong William H. , Kuhn John G. , Mischel Paul S. , Mehta Minesh P. , Cloughesy Timothy F. , Mellinghoff Ingo K.
Published: April 2023

mp3 file (11 MB). In the May edition of the Cancer Discovery podcast, Science Writer Elizabeth McKenna talks with Ingo K. Mellinghoff about his paper, which suggests that the disappointing clinical activity of first-generation EGFR inhibitors in glioblastoma versus lung cancer may be attributed to the different conformational requirements of mutant EGFR in these two cancer types.
Press Conference from Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non–Small Cell Lung Cancer
Authors: Juergens Rosalyn A. , Wrangle John , Vendetti Frank P. , Murphy Sara C. , Zhao Ming , Coleman Barbara , Sebree Rosa , Rodgers Kristen , Hooker Craig M. , Franco Noreli , Lee Beverly , Tsai Salina , Delgado Igor Espinoza , Rudek Michelle A. , Belinsky Steven A. , Herman James G. , Baylin Stephen B. , Brock Malcolm V. , Rudin Charles M.
Published: April 2023

mp3 file (49.6MB). Patients with recurrent metastatic non-small cell lung cancer have a morbid prognosis, but a new epigenetic therapy may have potential for this population. Cancer Discovery Editors-in-Chief Jose Baselga, M.D., Ph.D. and Lewis C. Cantley, Ph.D. moderated a press conference about this research on Wednesday, Nov. 9, 2011.
Supplementary Figure Legend and Methods from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment
Authors: Braas Daniel , Ahler Ethan , Tam Brenna , Nathanson David , Riedinger Mirielle , Benz Matthias R. , Smith Kathleen B. , Eilber Fritz C. , Witte Owen N. , Tap William D. , Wu Hong , Christofk Heather R.
Published: April 2023

PDF file - 114K
Supplementary Figure 9 from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment
Authors: Braas Daniel , Ahler Ethan , Tam Brenna , Nathanson David , Riedinger Mirielle , Benz Matthias R. , Smith Kathleen B. , Eilber Fritz C. , Witte Owen N. , Tap William D. , Wu Hong , Christofk Heather R.
Published: April 2023

PDF file - 148K, Supplemental Figure 9: dCK, CDA and DCTD expression levels vary in primary liposarcoma tumors.
Supplementary Figure 5 from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment
Authors: Braas Daniel , Ahler Ethan , Tam Brenna , Nathanson David , Riedinger Mirielle , Benz Matthias R. , Smith Kathleen B. , Eilber Fritz C. , Witte Owen N. , Tap William D. , Wu Hong , Christofk Heather R.
Published: April 2023

PDF file - 91K, Supplemental Figure 5: Knockdown of dCK expression does not change proliferation or alter glucose, lactate, and glutamine metabolism in liposarcoma cell lines.
Interview with Dr. Herrero from Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica
Authors: Herrero Rolando , Wacholder Sholom , Rodríguez Ana C. , Solomon Diane , González Paula , Kreimer Aimee R. , Porras Carolina , Schussler John , Jiménez Silvia , Sherman Mark E. , Quint Wim , Schiller John T. , Lowy Douglas R. , Schiffman Mark , Hildesheim Allan
Published: April 2023

mp3 file (6.7 MB). In the October edition of the Cancer Discovery podcast, Executive Editor Judy Quong talks with Rolando Herrero about his paper, which describes a community-based randomized clinical trial for the prevention of persistent human papillomavirus infection by an HPV16/18 vaccine.
Supplementary Figure 10 from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment
Authors: Braas Daniel , Ahler Ethan , Tam Brenna , Nathanson David , Riedinger Mirielle , Benz Matthias R. , Smith Kathleen B. , Eilber Fritz C. , Witte Owen N. , Tap William D. , Wu Hong , Christofk Heather R.
Published: April 2023

PDF file - 95K, Supplemental Figure 10: PBS treatment does not affect tumor growth of scramble- and dCK-knockdown liposarcomas.
Supplementary Methods, Tables 1-9, Figure Legends 1-3 from High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
Authors: Wagle Nikhil , Berger Michael F. , Davis Matthew J. , Blumenstiel Brendan , DeFelice Matthew , Pochanard Panisa , Ducar Matthew , Van Hummelen Paul , MacConaill Laura E. , Hahn William C. , Meyerson Matthew , Gabriel Stacey B. , Garraway Levi A.
Published: April 2023

PDF file - 141K
Supplementary Figure Legends 1-2 from Increased Levels of COX-2 and Prostaglandin E2 Contribute to Elevated Aromatase Expression in Inflamed Breast Tissue of Obese Women
Authors: Subbaramaiah Kotha , Morris Patrick G. , Zhou Xi Kathy , Morrow Monica , Du Baoheng , Giri Dilip , Kopelovich Levy , Hudis Clifford A. , Dannenberg Andrew J.
Published: April 2023

PDF file - 73K
Supplementary Table 4 from Molecular Ontogeny of Donor-Derived Follicular Lymphomas Occurring after Hematopoietic Cell Transplantation
Authors: Weigert Oliver , Kopp Nadja , Lane Andrew A. , Yoda Akinori , Dahlberg Suzanne E. , Neuberg Donna , Bahar Anita Y. , Chapuy Bjoern , Kutok Jeffery L. , Longtine Janina A. , Kuo Frank C. , Haley Terry , Salois Maura , Sullivan Timothy J. , Fisher David C. , Fox Edward A. , Rodig Scott J. , Antin Joseph H. , Weinstock David M.
Published: April 2023

PDF file - 290K
Supplementary Table 3 from Molecular Ontogeny of Donor-Derived Follicular Lymphomas Occurring after Hematopoietic Cell Transplantation
Authors: Weigert Oliver , Kopp Nadja , Lane Andrew A. , Yoda Akinori , Dahlberg Suzanne E. , Neuberg Donna , Bahar Anita Y. , Chapuy Bjoern , Kutok Jeffery L. , Longtine Janina A. , Kuo Frank C. , Haley Terry , Salois Maura , Sullivan Timothy J. , Fisher David C. , Fox Edward A. , Rodig Scott J. , Antin Joseph H. , Weinstock David M.
Published: April 2023

PDF file - 114K
Supplementary Figure 3 from Molecular Ontogeny of Donor-Derived Follicular Lymphomas Occurring after Hematopoietic Cell Transplantation
Authors: Weigert Oliver , Kopp Nadja , Lane Andrew A. , Yoda Akinori , Dahlberg Suzanne E. , Neuberg Donna , Bahar Anita Y. , Chapuy Bjoern , Kutok Jeffery L. , Longtine Janina A. , Kuo Frank C. , Haley Terry , Salois Maura , Sullivan Timothy J. , Fisher David C. , Fox Edward A. , Rodig Scott J. , Antin Joseph H. , Weinstock David M.
Published: April 2023

PDF file - 109K
Supplementary Methods and Legends from Targeting the Wnt Pathway in Synovial Sarcoma Models
Authors: Barham Whitney , Frump Andrea L. , Sherrill Taylor P. , Garcia Christina B. , Saito-Diaz Kenyi , VanSaun Michael N. , Fingleton Barbara , Gleaves Linda , Orton Darren , Capecchi Mario R. , Blackwell Timothy S. , Lee Ethan , Yull Fiona , Eid Josiane E.
Published: April 2023

Supplementary Methods and Legends - PDF file 130K, Methods:Additional information on experimental techniques Legends: describing supplementary figures
Supplementary Table 4 from Outlier Kinase Expression by RNA Sequencing as Targets for Precision Therapy
Authors: Kothari Vishal , Wei Iris , Shankar Sunita , Kalyana-Sundaram Shanker , Wang Lidong , Ma Linda W. , Vats Pankaj , Grasso Catherine S. , Robinson Dan R. , Wu Yi-Mi , Cao Xuhong , Simeone Diane M. , Chinnaiyan Arul M. , Kumar-Sinha Chandan
Published: April 2023

XLSX file - 613K, RNA-Seq data for matched primary pancreatic adenocarcinoma xenograft tissue, DS-08-947, and derived xenograft cell line.
Supplementary Table 1 from Outlier Kinase Expression by RNA Sequencing as Targets for Precision Therapy
Authors: Kothari Vishal , Wei Iris , Shankar Sunita , Kalyana-Sundaram Shanker , Wang Lidong , Ma Linda W. , Vats Pankaj , Grasso Catherine S. , Robinson Dan R. , Wu Yi-Mi , Cao Xuhong , Simeone Diane M. , Chinnaiyan Arul M. , Kumar-Sinha Chandan
Published: April 2023

XLSX file - 2238K, Complete kinome compendium of all tissue types by RNA-Seq.
Supplementary Figure 6 from Oncogenic and Wild-type Ras Play Divergent Roles in the Regulation of Mitogen-Activated Protein Kinase Signaling
Authors: Young Amy , Lou David , McCormick Frank
Published: April 2023

PDF file - 54K, Combining oncogenic Ras depletion with EGFR inhibition in the MIA PaCa-2 and RD cell lines
Supplementary Figures 5 - 8 from Outlier Kinase Expression by RNA Sequencing as Targets for Precision Therapy
Authors: Kothari Vishal , Wei Iris , Shankar Sunita , Kalyana-Sundaram Shanker , Wang Lidong , Ma Linda W. , Vats Pankaj , Grasso Catherine S. , Robinson Dan R. , Wu Yi-Mi , Cao Xuhong , Simeone Diane M. , Chinnaiyan Arul M. , Kumar-Sinha Chandan
Published: April 2023

PDF file - 4323K, This file contains supplemental figures providing results of additional experiments supporting sample-specific sensitivities upon targeting of outlier kinases.
Supplementary Figure 5 from Oncogenic and Wild-type Ras Play Divergent Roles in the Regulation of Mitogen-Activated Protein Kinase Signaling
Authors: Young Amy , Lou David , McCormick Frank
Published: April 2023

PDF file - 135K, Depletion of oncogenic Ras sensitizes cells to the acute activation of various receptor tyrosine kinases in a cell line-dependent manner
Supplementary Figures 1-20 from Discovery of Mdm2-MdmX E3 Ligase Inhibitors Using a Cell-Based Ubiquitination Assay
Authors: Herman Ariel G. , Hayano Miki , Poyurovsky Masha V. , Shimada Kenichi , Skouta Rachid , Prives Carol , Stockwell Brent R.
Published: April 2023

PDF file - 907K
Supplementary Table 5a from Essential Gene Profiles in Breast, Pancreatic, and Ovarian Cancer Cells
Authors: Marcotte Richard , Brown Kevin R. , Suarez Fernando , Sayad Azin , Karamboulas Konstantina , Krzyzanowski Paul M. , Sircoulomb Fabrice , Medrano Mauricio , Fedyshyn Yaroslav , Koh Judice L.Y. , van Dyk Dewald , Fedyshyn Bohdana , Luhova Marianna , Brito Glauber C. , Vizeacoumar Franco J. , Vizeacoumar Frederick S. , Datti Alessandro , Kasimer Dahlia , Buzina Alla , Mero Patricia , Misquitta Christine , Normand Josee , Haider Maliha , Ketela Troy , Wrana Jeffrey L. , Rottapel Robert , Neel Benjamin G. , Moffat Jason
Published: April 2023

XLS file - 22K
Supplementary Figure 2 from Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
Authors: Juvekar Ashish , Burga Laura N. , Hu Hai , Lunsford Elaine P. , Ibrahim Yasir H. , Balmañà Judith , Rajendran Anbazhagan , Papa Antonella , Spencer Katherine , Lyssiotis Costas A. , Nardella Caterina , Pandolfi Pier Paolo , Baselga José , Scully Ralph , Asara John M. , Cantley Lewis C. , Wulf Gerburg M.
Published: April 2023

PDF file - 526K, FDG-uptake and CT-PET scanning of mice before and after 2 weeks of treatment with NVP-BKM120. Tumor-bearing female MMTV-CreBRCA1f/fp53+/- mice were imaged with PET-CT scans before and after treatments with NVP-BKM120 at 50 mg/kg/day. Yellow arrows in the upper panel point to the dominant mass in each mouse before treatment. Synchronous additional tumors are indicated with green arrows. The lower panel displays the same mice imaged within 3 hours of treatment with a two-week course of NVP-BKM120 at 50 mg/kg/day. Percent decrease of FDG-uptake in the dominant mass was determined as described in Materials and Methods
Supplementary Figure 1 from Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
Authors: Juvekar Ashish , Burga Laura N. , Hu Hai , Lunsford Elaine P. , Ibrahim Yasir H. , Balmañà Judith , Rajendran Anbazhagan , Papa Antonella , Spencer Katherine , Lyssiotis Costas A. , Nardella Caterina , Pandolfi Pier Paolo , Baselga José , Scully Ralph , Asara John M. , Cantley Lewis C. , Wulf Gerburg M.
Published: April 2023

PDF file - 319K, Target inhibition after treatments with NVP-BKM120 in vivo. Tumor-bearing MMTV-CreBRCA1f/fp53+/- mice were biopsied before treatment, and tumor tissues harvested within 3 hours after the last treatment. Tissues were fixed and processed for immunohistochemistry with anti-phospho AKT (S473) antibodies. 400 x magnification
Supplementary Methods from Essential Gene Profiles in Breast, Pancreatic, and Ovarian Cancer Cells
Authors: Marcotte Richard , Brown Kevin R. , Suarez Fernando , Sayad Azin , Karamboulas Konstantina , Krzyzanowski Paul M. , Sircoulomb Fabrice , Medrano Mauricio , Fedyshyn Yaroslav , Koh Judice L.Y. , van Dyk Dewald , Fedyshyn Bohdana , Luhova Marianna , Brito Glauber C. , Vizeacoumar Franco J. , Vizeacoumar Frederick S. , Datti Alessandro , Kasimer Dahlia , Buzina Alla , Mero Patricia , Misquitta Christine , Normand Josee , Haider Maliha , Ketela Troy , Wrana Jeffrey L. , Rottapel Robert , Neel Benjamin G. , Moffat Jason
Published: April 2023

PDF file - 217K
Supplementary Figure 1 from Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders
Authors: Hyman David M. , Diamond Eli L. , Vibat Cecile Rose T. , Hassaine Latifa , Poole Jason C. , Patel Minal , Holley Veronica R. , Cabrilo Goran , Lu Timothy T. , Arcila Maria E. , Chung Young Rock , Rampal Raajit , Lacouture Mario E. , Rosen Neal , Meric-Bernstam Funda , Baselga José , Kurzrock Razelle , Erlander Mark G. , Janku Filip , Abdel-Wahab Omar
Published: April 2023

Supplemental Figure 1: BRAFV600E mutant allele burden in cell-free DNA (cfDNA) of urine and plasma from treatment naïve patients based on BRAFV600E tissue genotype result.
Supplementary Tables from Epithelial-to-Mesenchymal Transition Activates PERK–eIF2α and Sensitizes Cells to Endoplasmic Reticulum Stress
Authors: Feng Yu-xiong , Sokol Ethan S. , Del Vecchio Catherine A. , Sanduja Sandhya , Claessen Jasper H.L. , Proia Theresa A. , Jin Dexter X. , Reinhardt Ferenc , Ploegh Hidde L. , Wang Qiu , Gupta Piyush B.
Published: April 2023

PDF file 59K, Table S1: GSEA of microarray data from Cmp302-treated cells; Table S2: ECM gene expression in luminal and basal-B breast cancer lines
Supplementary Figures from Epithelial-to-Mesenchymal Transition Activates PERK–eIF2α and Sensitizes Cells to Endoplasmic Reticulum Stress
Authors: Feng Yu-xiong , Sokol Ethan S. , Del Vecchio Catherine A. , Sanduja Sandhya , Claessen Jasper H.L. , Proia Theresa A. , Jin Dexter X. , Reinhardt Ferenc , Ploegh Hidde L. , Wang Qiu , Gupta Piyush B.
Published: April 2023

Supplementary Figures PDF file 390K, Fig. S1: Validation of EMT-selective small molecules; Fig. S2: EMT increases sensitivity to ER stressors; Fig. S3: Cells that undergo an EMT are highly secretory; Fig. S4: Inhibition of ECM genes abrogates migration and ER stress sensitivity; Fig. S5: BiP inhibition activates the UPR in basal-B but not luminal breast cancer cells; Fig. S6: EMT activates PERK-eIF2a but not IRE1-XBP1; Fig. S7: Effects of PERK inhibitor on cellular proliferation; Fig. S8: EMT primary breast cancer cells are more sensitive to ER stressors.
Supplementary Table S9 from Discovery of Biomarkers Predictive of GSI Response in Triple-Negative Breast Cancer and Adenoid Cystic Carcinoma
Authors: Stoeck Alexander , Lejnine Serguei , Truong Andrew , Pan Li , Wang Hongfang , Zang Chongzhi , Yuan Jing , Ware Chris , MacLean John , Garrett-Engele Philip W. , Kluk Michael , Laskey Jason , Haines Brian B. , Moskaluk Christopher , Zawel Leigh , Fawell Stephen , Gilliland Gary , Zhang Theresa , Kremer Brandon E. , Knoechel Birgit , Bernstein Bradley E. , Pear Warren S. , Liu X. Shirley , Aster Jon C. , Sathyanarayanan Sriram
Published: April 2023

human Breast tumor Notch gene coverage annotations.
Supplementary Table S10 from Discovery of Biomarkers Predictive of GSI Response in Triple-Negative Breast Cancer and Adenoid Cystic Carcinoma
Authors: Stoeck Alexander , Lejnine Serguei , Truong Andrew , Pan Li , Wang Hongfang , Zang Chongzhi , Yuan Jing , Ware Chris , MacLean John , Garrett-Engele Philip W. , Kluk Michael , Laskey Jason , Haines Brian B. , Moskaluk Christopher , Zawel Leigh , Fawell Stephen , Gilliland Gary , Zhang Theresa , Kremer Brandon E. , Knoechel Birgit , Bernstein Bradley E. , Pear Warren S. , Liu X. Shirley , Aster Jon C. , Sathyanarayanan Sriram
Published: April 2023

Human breast tumor GE Notch Pathway.